Advertisement

Hypofractionation for Lung Tumors (Primary Malignant, Secondary Malignant)

  • Joseph M. Caster
  • Achilles J. Fakiris
  • Michael V. Lawrence
  • Eric C. Scheriber
  • Lawrence B. Marks
Chapter

Abstract

Surgery has traditionally been the standard of care for early-stage (T1–T2 N0) NSCLC and lung metastases as local control with conventionally fractionated EBRT was clearly inferior to surgical resection. However, the emergence of SBRT (1–5 fractions of >5 Gy/fx) for lung lesions is challenging this standard as local control rates of >80–95% can be achieved with either modality. Less extreme hypofractionation (15–25 fractions of 2.5–3.5 Gy/fx) regimens have also been utilized in an attempt to escalate the BED of radiation for more advanced (stages III–IV) NSCLC. Clinical experience has demonstrated that while these approaches can produce encouraging tumor control rates, they are not without the risk of severe, even fatal complications as a result of damage to the many critical structures located in the thorax. This chapter will review the sizeable literature for lung SBRT and hypofractionation regimens and highlight the technical considerations that are necessary to properly utilize these techniques.

Keywords

Lung cancer Hypofractionation SBRT SABR NSCLC 

References

  1. 1.
    Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27(10):1579–84.CrossRefPubMedGoogle Scholar
  2. 2.
    Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Yeo SG, Kim MJ. Stereotactic body radiation therapy for the treatment of a post-chemotherapy remnant lung mass in extensive-stage small-cell lung cancer: a case report. Exp Ther Med. 2016;12(2):1185–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bral S, Gevaert T, Linthout N, et al. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. Int J Radiat Oncol Biol Phys. 2011;80(5):1343–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Trakul N, Harris JP, Le QT, et al. Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac Oncol. 2012;7(9):1462–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Owen D, Olivier KR, Song L, et al. Safety and tolerability of SBRT after high-dose external beam radiation to the lung. Front Oncol. 2014;4:376.CrossRefPubMedGoogle Scholar
  7. 7.
    Kilburn JM, Kuremsky JG, Blackstock AW, et al. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol. 2014;110(3):505–10.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Li Q, Swanick CW, Allen PK, et al. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol. 2014;112(2):256–61.CrossRefPubMedGoogle Scholar
  9. 9.
    Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. 2011;6(12):2036–43.CrossRefPubMedGoogle Scholar
  10. 10.
    Hearn JW, Videtic GM, Djemil T, Stephans KL. Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT. Int J Radiat Oncol Biol Phys. 2014;90(2):402–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Videtic GM, Stephans K, Reddy C, et al. Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control. Int J Radiat Oncol Biol Phys. 2010;77(2):344–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Okunieff P, Petersen AL, Philip A, et al. Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol. 2006;45(7):808–17.CrossRefPubMedGoogle Scholar
  13. 13.
    Nagata Y, Hiraoka M, Shibata T, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan clinical oncology group study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93(5):989–96.CrossRefPubMedGoogle Scholar
  14. 14.
    Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63(5):1427–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Shibamoto Y, Hashizume C, Baba F, et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: a multicenter study. Cancer. 2012;118(8):2078–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Vahdat S, Oermann EK, Collins SP, et al. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment. J Hematol Oncol. 2010;3:6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Trovo M, Minatel E, Durofil E, et al. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;88(5):1114–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Cheung P, Faria S, Ahmed S, et al. Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25. J Natl Cancer Inst. 2014;106(8):dju164.CrossRefPubMedGoogle Scholar
  21. 21.
    Agolli L, Valeriani M, Bracci S, et al. Hypofractionated image-guided radiation therapy (3Gy/fraction) in patients affected by inoperable advanced-stage non-small cell lung cancer after long-term follow-up. Anticancer Res. 2015;35(10):5693–700.PubMedGoogle Scholar
  22. 22.
    Chang HJ, Ko HL, Lee CY, et al. Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy. Radiat Oncol. 2012;7:222.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Belderbos J, Uitterhoeve L, van Zandwijk N, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer. 2007;43(1):114–21.CrossRefPubMedGoogle Scholar
  24. 24.
    Walraven I, van den Heuvel M, van Diessen J, et al. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiother Oncol. 2016;118(3):442–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078–101.CrossRefPubMedGoogle Scholar
  26. 26.
    Liu YE, Lin Q, Meng FJ, et al. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study. Radiat Oncol. 2013;8(1):198.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cannon DM, Mehta MP, Adkison JB, et al. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2013;31(34):4343–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124(5):1946–55.CrossRefPubMedGoogle Scholar
  29. 29.
    Kopek N, Paludan M, Petersen J, Hansen AT, Grau C, Hoyer M. Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol. 2009;93(3):402–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Haseltine JM, Rimner A, Gelblum DY, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol. 2016;6(2):e27–33.CrossRefPubMedGoogle Scholar
  31. 31.
    Baba F, Shibamoto Y, Ogino H, et al. Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size. Radiat Oncol. 2010;5:81.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28(6):928–35.CrossRefPubMedGoogle Scholar
  33. 33.
    Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101(7):1623–31.CrossRefPubMedGoogle Scholar
  34. 34.
    Kelly P, Balter PA, Rebueno N, et al. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys. 2010;78(5):1387–93.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Nyman J, Johansson KA, Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients. Lung Cancer. 2006;51(1):97–103.CrossRefPubMedGoogle Scholar
  36. 36.
    Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(3):796–801.CrossRefPubMedGoogle Scholar
  37. 37.
    Modh A, Rimner A, Williams E, et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014;90(5):1168–76.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Coon D, Gokhale AS, Burton SA, Heron DE, Ozhasoglu C, Christie N. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning. Clin Lung Cancer. 2008;9(4):217–21.CrossRefPubMedGoogle Scholar
  39. 39.
    Lindberg K, Nyman J, Riesenfeld Kallskog V, et al. Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience. Acta Oncol. 2015;54(8):1096–104.CrossRefPubMedGoogle Scholar
  40. 40.
    Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer. 2010;68(1):72–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27(20):3290–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85(3):429–34.CrossRefPubMedGoogle Scholar
  43. 43.
    Shen ZT, Wu XH, Li B, Zhu XX. Clinical outcomes of CyberKnife stereotactic body radiotherapy for peripheral stage I non-small cell lung cancer. Med Oncol. 2015;32(3):55.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Song SY, Choi W, Shin SS, et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer. 2009;66(1):89–93.CrossRefPubMedGoogle Scholar
  45. 45.
    Hoopes DJ, Tann M, Fletcher JW, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer. 2007;56(2):229–34.CrossRefPubMedGoogle Scholar
  46. 46.
    Niibe Y, Yamashita H, Sekiguchi K, et al. Stereotactic body radiotherapy results for pulmonary oligometastases: a two-institution collaborative investigation. Anticancer Res. 2015;35(9):4903–8.PubMedGoogle Scholar
  47. 47.
    Baba F, Shibamoto Y, Tomita N, et al. Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results. Radiat Oncol. 2009;4:15.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Aibe N, Yamazaki H, Nakamura S, et al. Outcome and toxicity of stereotactic body radiotherapy with helical tomotherapy for inoperable lung tumor: analysis of Grade 5 radiation pneumonitis. J Radiat Res. 2014;55(3):575–82.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Harkenrider MM, Bertke MH, Dunlap NE. Stereotactic body radiation therapy for unbiopsied early-stage lung cancer: a multi-institutional analysis. Am J Clin Oncol. 2014;37(4):337–42.CrossRefPubMedGoogle Scholar
  50. 50.
    Baschnagel AM, Mangona VS, Robertson JM, Welsh RJ, Kestin LL, Grills IS. Lung metastases treated with image-guided stereotactic body radiation therapy. Clin Oncol (R Coll Radiol). 2013;25(4):236–41.CrossRefGoogle Scholar
  51. 51.
    Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2012;75(1):77–81.CrossRefPubMedGoogle Scholar
  52. 52.
    Patel NR, Lanciano R, Sura K, et al. Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses. J Radiat Oncol. 2015;4(1):65–70.CrossRefPubMedGoogle Scholar
  53. 53.
    Reyngold M, Wu AJ, McLane A, et al. Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). Radiat Oncol. 2013;8:99.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Maguire J, Khan I, McMenemin R, et al. SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status. Eur J Cancer. 2014;50(17):2939–49.CrossRefPubMedGoogle Scholar
  55. 55.
    Osti MF, Agolli L, Valeriani M, et al. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):e157–63.CrossRefPubMedGoogle Scholar
  56. 56.
    Cho KH, Ahn SJ, Pyo HR, et al. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study. Int J Radiat Oncol Biol Phys. 2009;74(5):1397–404.CrossRefPubMedGoogle Scholar
  57. 57.
    Jiang W, Wang JY, Wang JB, et al. Hypofractionated radiotherapy for medically inoperable stage I non-small cell lung cancer. Thorac Cancer. 2016;7(3):296–303.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Joseph M. Caster
    • 1
  • Achilles J. Fakiris
    • 2
  • Michael V. Lawrence
    • 3
  • Eric C. Scheriber
    • 3
  • Lawrence B. Marks
    • 3
  1. 1.Department of Radiation OncologyUniversity of IowaIowa CityUSA
  2. 2.Department of Radiation OncologyRex Hospital, University of North Carolina Affiliate HospitalRaleighUSA
  3. 3.Department of Radiation OncologyUniversity of North Carolina HospitalsChapel HillUSA

Personalised recommendations